CERUS CORP (CERS)

US1570851014 - Common Stock

2.21  0 (0%)

After market: 2.24 +0.03 (+1.36%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CERUS CORP

NASDAQ:CERS (2/26/2024, 7:24:13 PM)

After market: 2.24 +0.03 (+1.36%)

2.21

0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap400.45M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CERS Daily chart

Company Profile

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 309 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as platelets, plasma, red blood cells. Its product or product candidate under development include INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, red blood cell and IFC transfusion products.

Company Info

CERUS CORP

1220 Concord Ave Ste 600, 2550 Stanwell Drive

Concord CALIFORNIA 94520

P: 19252886000

CEO: William M. Greenman

Employees: 309

Website: https://www.cerus.com/

CERS News

News Image7 days ago - Cerus CorporationCerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024
News Image26 days ago - Cerus CorporationCerus Corporation to Participate in Upcoming Investor Conferences
News Imagea month ago - The Motley FoolCathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The widely followed growth investor keeps making moves.

News Imagea month ago - Seeking AlphaCantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS

Cantor Fitzgerald picks AVITA Medical (RCEL) as its best 2024 medtech idea, while remaining bullish on AXGN, CERS, ELUT, XGN, NNOX, NPCE, NYXH, SIBN, and PACB. Read more here.

News Imagea month ago - The Motley Fool3 Growth Stocks That Could Go Parabolic in 2024

These innovation-oriented companies could take flight this year.

News Image2 months ago - Seeking AlphaCerus says preliminary product revenue for Q4 totaled $46.8M (NASDAQ:CERS)

Cerus Corporation reports 6% increase in fourth-quarter product revenue. Full-year unaudited revenue for 2023 expected to be $156.4 million.

CERS Twits

Here you can normally see the latest stock twits on CERS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example